ArticleBreast cancer research and treatment2013
Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment.
Article in Breast cancer research and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Statins and prognosis of female breast cancer: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Adherence to cardiovascular disease risk factor medications among patients with cancer: a systematic review.Journal of cancer survivorship : research and practice · 2023Pooled it
- Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis.BMJ open · 2021Pooled it
- Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial.BMC family practice · 2021Trial
- Changes in compliance with cardiovascular medication after a breast cancer diagnosis: a latent class trajectory analysis using French nationwide data.Breast cancer research and treatment · 2026Article
- Article
- Article
- Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer.JAMA network open · 2023Article
- Cardiometabolic Comorbidities in Cancer Survivors:JACC. CardioOncology · 2022Review
- Article
- Changes in chronic medication adherence in older adults with cancer versus matched cancer-free cohorts.Journal of geriatric oncology · 2021Article
- Rates of underuse of statins among cancer survivors versus controls: NHANES 2011-2016.Journal of cancer survivorship : research and practice · 2020Article
- Emerging roles of low-density lipoprotein in the development and treatment of breast cancer.Lipids in health and disease · 2019Review
- Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer.Journal of cancer survivorship : research and practice · 2018Article
- Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation.Cancer · 2018Article
- Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis.Pharmacoepidemiology and drug safety · 2017Article
- Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors.Breast cancer research and treatment · 2017Article
- Statin Adherence: Does Gender Matter?Current atherosclerosis reports · 2016Review
- Single subject design: Use of time series analyses in a small cohort to understand adherence with a prescribed fluid restriction.Applied nursing research : ANR · 2015Article
- Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014 · on this mapObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Breast cancer tends to arise in older women who are also burdened with comorbidities such as cardiovascular disease (CVD). Increasing numbers of breast cancer survivors and an aging population warrant a better understanding of CVD management and adherence to preventive therapies. We estimated adherence to statins and therapeutic goal lipid values during the year before breast cancer diagnosis or baseline, treatment period, and in subsequent years of clinical management among breast cancer survivors. We sampled women from an existing cohort of 4,221 women diagnosed with incident early stage (I, II) invasive breast cancer from 1990 to 2008 and enrolled in a large integrated group practice health plan. Among prevalent statin users (N = 1,393), medication adherence and persistence were measured by medication possession ratio (MPR), % adherent (MPR < 0.80), and discontinuation rates. Laboratory data on LDL and HDL were obtained for the coinciding periods. Mean MPR for statin use (0.78 vs. 0.68; P < 0.001) and proportion adherent (67.0 vs. 51.9 %; P < 0.001) declined from baseline to the treatment period. Mean LDL (143 mg/dL baseline vs. 150 mg/dL treatment period; P < 0.001) and proportion not at LDL goal (60.1 vs. 70.8 %; P < 0.001) coincided with decreases in adherence. During treatment, non-adherent statin users had the highest mean LDL (160.4 mg/dL) and proportion not at goal LDL (91.8 %) overall. Adherence did not return to baseline in subsequent years following treatment although LDL levels did. HDL did not differ by periods of interest or adherence levels. Adherence to statins in this population was poor, particularly in the treatment period, and lagged in returning to baseline. Understanding the influence of life events such as cancer diagnosis and treatment on management of comorbidities and adherence to preventive therapies are important to the growing population of breast cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.